Pasar al contenido principal

DESVELANDO EL PAPEL DE LA NEDILACION EN EL ESTRES NUTRICIONAL

PID2020-117116RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario ASOCIACION CENTRO DE INVESTIGACION COOP EN BIOCIENCIAS CIC BIOGUNE

Resultados relacionados

Resultados totales (Incluyendo duplicados): 17
Encontrada(s) 1 página(s)

BULERIA. Repositorio Institucional de la Universidad de León
Publicación Artículo científico (JournalArticle)

Enhanced mitochondrial activity reshapes a gut microbiota profile that delays NASH progression

  • Juárez Fernández, María
  • Goikoetxea Usandizaga, Naroa
  • Porras Sanabria, David
  • García Mediavilla, María Victoria
  • Bravo, Miren
  • Serrano Maciá, Marina
  • Simón, Jorge
  • Delgado, Teresa C.
  • Lachiondo Ortega, Sofía
  • Martínez Flórez, Susana
  • Lorenzo, Óscar
  • Rincón, Mercedes
  • Varela Rey, Marta
  • Abecia, Leticia
  • Rodríguez, Héctor
  • Anguita, Juan
  • Nistal González, Maria Esther
  • Martínez Chantar, María Luz
  • Sánchez Campos, Sonia
[EN] Background and Aims: Recent studies suggest that mitochondrial dysfunction promotes progression to NASH by aggravating the gut-liver status. However, the underlying mechanism remains unclear. Herein, we hypothesized that enhanced mitochondrial activity might reshape a specific microbiota signature that, when transferred to germ-free (GF) mice, could delay NASH progression. Approach and Results: Wild-type and methylation-controlled J protein knockout (MCJ-KO) mice were fed for 6 weeks with either control or a choline-deficient, L-amino acid–defined, high-fat diet (CDA-HFD). One mouse of each group acted as a donor of cecal microbiota to GF mice, who also underwent the CDA-HFD model for 3 weeks. Hepatic injury, intestinal barrier, gut microbiome, and the associated fecal metabolome were then studied. Following 6 weeks of CDA-HFD, the absence of methylation-controlled J protein, an inhibitor of mitochondrial complex I activity, reduced hepatic injury and improved gut-liver axis in an aggressive NASH dietary model. This effect was transferred to GF mice through cecal microbiota transplantation. We suggest that the specific microbiota profile of MCJ-KO, characterized by an increase in the fecal relative abundance of Dorea and Oscillospira genera and a reduction in AF12, Allboaculum, and [Ruminococcus], exerted protective actions through enhancing short-chain fatty acids, nicotinamide adenine dinucleotide (NAD+) metabolism, and sirtuin activity, subsequently increasing fatty acid oxidation in GF mice. Importantly, we identified Dorea genus as one of the main modulators of this microbiota-dependent protective phenotype. Conclusions: Overall, we provide evidence for the relevance of mitochondria–microbiota interplay during NASH and that targeting it could be a valuable therapeutic approach., SI, Publicación en abierto financiada por el Consorcio de Bibliotecas Universitarias de Castilla y León (BUCLE), con cargo al Programa Operativo 2014ES16RFOP009 FEDER 2014-2020 DE CASTILLA Y LEÓN, Actuación:20007-CL - Apoyo Consorcio BUCLE
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

Hepatocyte-specific O-GlcNAc transferase downregulation ameliorates nonalcoholic steatohepatitis by improving mitochondrial function

  • González Rellán, María Jesús
  • Parracho, Tamara
  • Heras, Violeta
  • Rodríguez, Amaia
  • Fernández Fondevila, Marcos
  • Novoa Deaño, Eva María
  • Lima, Natalia
  • Varela Rey, Marta María
  • Senra, Ana
  • Chantada Vázquez, María del Pilar
  • Ameneiro, Cristina
  • Bernardo, Ganeko
  • Fernández-Ramos, David
  • Lopitz-Otsoa, Fernando
  • Bilbao, Jon
  • Guallar Artal, Diana
  • Fidalgo, Miguel
  • Bravo López, Susana Belén
  • Diéguez, Carlos
  • Martínez-Chantar, María Luz
  • Millet, Óscar
  • Mato, José M.
  • Schwaninger, Markus
  • Prevot, Vincent
  • Crespo, Javier
  • Frühbeck, Gema
  • Iruzubieta, Paula
  • Nogueiras Pozo, Rubén
Objective O-GlcNAcylation is a post-translational modification that directly couples the processes of nutrient sensing, metabolism, and signal transduction, affecting protein function and localization, since the O-linked N-acetylglucosamine moiety comes directly from the metabolism of glucose, lipids, and amino acids. The addition and removal of O-GlcNAc of target proteins are mediated by two highly conserved enzymes: O-linked N-acetylglucosamine (O-GlcNAc) transferase (OGT) and O-GlcNAcase (OGA), respectively. Deregulation of O-GlcNAcylation has been reported to be associated with various human diseases such as cancer, diabetes, and cardiovascular diseases. The contribution of deregulated O-GlcNAcylation to the progression and pathogenesis of NAFLD remains intriguing, and a better understanding of its roles in this pathophysiological context is required to uncover novel avenues for therapeutic intervention. By using a translational approach, our aim is to describe the role of OGT and O-GlcNAcylation in the pathogenesis of NAFLD. Methods We used primary mouse hepatocytes, human hepatic cell lines and in vivo mouse models of steatohepatitis to manipulate O-GlcNAc transferase (OGT). We also studied OGT and O-GlcNAcylation in liver samples from different cohorts of people with NAFLD. Results O-GlcNAcylation was upregulated in the liver of people and animal models with steatohepatitis. Downregulation of OGT in NAFLD-hepatocytes improved diet-induced liver injury in both in vivo and in vitro models. Proteomics studies revealed that mitochondrial proteins were hyper-O-GlcNAcylated in the liver of mice with steatohepatitis. Inhibition of OGT is able to restore mitochondrial oxidation and decrease hepatic lipid content in in vitro and in vivo models of NAFLD. Conclusions These results demonstrate that deregulated hyper-O-GlcNAcylation favors NAFLD progression by reducing mitochondrial oxidation and promoting hepatic lipid accumulation
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A Shortcut from Metabolic-Associated Fatty Liver Disease (MAFLD) to Hepatocellular Carcinoma (HCC): c-MYC a Promising Target for Preventative Strategies and Individualized Therapy

  • Guo, Feifei
  • Estévez-Vázquez, Olga
  • Benedé-Ubieto, Raquel
  • Maya-Miles, Douglas
  • Zheng, Kang
  • Gallego-Durán, Rocío
  • Rojas, Ángela
  • Ampuero, Javier
  • Romero-Gómez, Manuel
  • Philip, Kaye
  • Egbuniwe, Isioma U.
  • Chen, Chaobo
  • Simon, Jorge
  • Delgado, Teresa C.
  • Martínez-Chantar, María Luz
  • Sun, Jie
  • Reissing, Johanna
  • Bruns, Tony
  • Lamas-Paz, Arantza
  • Gómez del Moral, Manuel
  • Woitok, Marius Maximilian
  • Vaquero, Javier
  • Regueiro, José R.
  • Liedtke, Christian
  • Trautwein, Christian
  • Bañares, Rafael
  • Cubero, Javier
  • Nevzorova, Yulia A.
Metabolic-associated fatty liver disease (MAFLD) has risen as one of the leading etiologies for hepatocellular carcinoma (HCC). Oncogenes have been suggested to be responsible for the high risk of MAFLD-related HCC. We analyzed the impact of the proto-oncogene c-MYC in the development of human and murine MAFLD and MAFLD-associated HCC., This work was supported by the MINECO Retos SAF2016-78711, SAF2017-87919-R, PID2020-117827RB-IOO, PID2020-117941RB-IOO, PID2020-117116RB-I00, EXOHEP-CM S2017/BMD-3727, NanoLiver-CM Y2018/NMT-4949, AMMF 2018/117, COST Action CA17112 and UCM-25/2019, La Caixa Foundation Program HR17-00601; Asociación Española Contra el Cáncer (AECC PROYE20084REGU); the German Research Foundation (SFB1382 Project ID 403224013/A02). FJC and YAN are Ramón y Cajal Researchers RYC-2014-15242 and RYC-2015-17438, respectively. FJC is a Gilead Liver Research Scholar. The research group belongs to the validated Research Groups Ref. 970935 “Liver Pathophysiology”, 920631 “Lymphocyte immunobiology”, 920361 “Inmunogenética e inmunología de las mucosas” and IBL-6 (imas12-associated). FG and KZ are Chinese Scholarship Council (CSC) fellows. O.E.-V is supported by Beca FPI associated to MINECO SAR2017-87919R and R.B.-U by programa de Financiación de Universidad Complutense de Madrid—Banco Santander, CT63/19. DMM contract is supported by CIBEREHD. DMM, MRG, AR, JA and RG receive support from the Andalusian government (Proyectos Estratégicos-Fondos Feder PE-0451-2018) and from the Instituto de Salud Carlos III (PI16/01842, PI19/01404; PI19/00589). TB is supported by the German Research Foundation (SFB1382 Project ID 403224013/B07)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Restoring cellular magnesium balance through Cyclin M4 protects against acetaminophen-induced liver damage

  • González-Recio, Irene
  • Simón, Jorge
  • Goikoetxea-Usandizaga, Naroa
  • Serrano-Maciá, Marina
  • Rodríguez-Agudo, Rubén
  • Lachiondo-Ortega, Sofía
  • Gil-Pitarch, Clàudia
  • Fernández-Rodríguez, Carmen
  • Castellana, Donatello
  • Latasa, Maria U.
  • Abecia, Leticia
  • Anguita, Juan
  • Delgado, Teresa C.
  • Iruzubieta, Paula
  • Crespo, Javier
  • Hardy, Serge
  • Petrov, Petar D.
  • Jover, Ramiro
  • Ávila, Matías A.
  • Martín, César
  • Schaeper, Ute
  • Tremblay, Michel L.
  • Dear, James W.
  • Masson, Steven
  • McCain, Misti
  • Reeves, Helen L.
  • Andrade, Raúl J.
  • Lucena, María Isabel
  • Buccella, Daniela
  • Martínez-Cruz, Luis Alfonso
  • Martínez-Chantar, María Luz
Acetaminophen overdose is one of the leading causes of acute liver failure and liver transplantation in the Western world. Magnesium is essential in several cellular processess. The Cyclin M family is involved in magnesium transport across cell membranes. Herein, we identify that among all magnesium transporters, only Cyclin M4 expression is upregulated in the liver of patients with acetaminophen overdose, with disturbances in magnesium serum levels. In the liver, acetaminophen interferes with the mitochondrial magnesium reservoir via Cyclin M4, affecting ATP production and reactive oxygen species generation, further boosting endoplasmic reticulum stress. Importantly, Cyclin M4 mutant T495I, which impairs magnesium flux, shows no effect. Finally, an accumulation of Cyclin M4 in endoplasmic reticulum is shown under hepatoxicity. Based on our studies in mice, silencing hepatic Cyclin M4 within the window of 6 to 24 h following acetaminophen overdose ingestion may represent a therapeutic target for acetaminophen overdose induced liver injury., This work was supported by Ministerio de Ciencia, Innovación y Universidades MICINN: PID2020-117116RB-I00 integrado en el Plan Estatal de Investigación Cientifica y Técnica y Innovación, cofinanciado con Fondos FEDER (to MLM-C), Ministerio de Ciencia e Innovación CONSOLIDER-INGENIO 2010 Program Grant CSD2008-00005 (to LAM-C); Spanish Ministry of Economy and Competitiveness Grant BFU2013-47531-R, BFU2016-77408-R, PID2019-109055RB-100 (to L.A.M.-C.) (MINECO/FEDER, UE); Asociación Española contra el Cáncer (MLM-C, TC-D), Fundación Científica de la Asociación Española Contra el Cáncer (AECC Scientific Foundation) Rare Tumor Calls 2017 (to M.L.M.-C.), La Caixa Foundation Program (to M.L.M.-C.), Fundacion BBVA UMBRELLA project (to M.L.M.-C.), Ayuda RYC2020-029316-I financiada por MICIN/AEI/10.13039/501100011033 (to TC-D), Plataforma de Investigación Clínica-SCReN (PT17 0017 0020) (to M.I.-L.), programa retos RTC2019-007125-1 (to M.L.M.-C, J.S.), Proyectos Investigacion en Salud DTS20/00138 (to M.L.M.-C., J.S), ERA-Net E-Rare EJP RD Joint Translational Call for Rare Diseases FIGHT-CNNM2 (EJPRD19-040) and from Instituto Carlos III, Spain (REF G95229142) (to L.A.M.-C.), US National Institutes of Health under grant CA217817 (to D.B.), Ciberehd_ISCIII_MINECO is funded by the Instituto de Salud Carlos III. We thank MINECO for the Severo Ochoa Excellence Accreditation to CIC bioGUNE (SEV-2016-0644) and PhD fellowship from MINECO (REF BES-2017-080435) awarded to I.G.-R. The collection and storage of patients tissues was supported by the Newcastle Biomedicine Biobank and the European Community’s Seventh Framework Programme (FP7/2001–2013) and Cancer Research UK awards Cancer Research UK grants C18342/A23390; C9380/A18084 and C9380/A26813., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Hepatic levels of S-adenosylmethionine regulate the adaptive response to fasting

  • Capelo-Diz, Alba
  • Lachiondo-Ortega, Sofía
  • Fernández Ramos, David
  • Cañas-Martín, Jorge
  • Goikoetxea-Usandizaga, Naroa
  • Serrano-Maciá, Marina
  • González-Rellán, María Jesús
  • Mosca, Laura
  • Blázquez-Vicens, Joan
  • Tinahones-Ruano, Alberto
  • Fondevila, Marcos F.
  • Buyan, Mason
  • Delgado, Teresa C.
  • Gutiérrez de Juan, Virginia
  • Ayuso-García, Paula
  • Sánchez-Rueda, Alejandro
  • Velasco-Aviles, Sergio
  • Fernández-Susavila, Héctor
  • Riobello-Suárez, Cristina
  • Dziechciarz, Bartlomiej
  • Montiel-Duarte, Cristina
  • Lopitz-Otsoa, Fernando
  • Bizkarguenaga, Maider
  • Bilbao-García, Jon
  • Bernardo-Seisdedos, Ganeko
  • Senra, Ana
  • Soriano-Navarro, Mario
  • Millet, Óscar
  • Díaz-Lagares, Ángel
  • Crujeiras, Ana B.
  • Bao-Caamano, Aida
  • Cabrera, Diana
  • van Liempd, Sebastiaan M.
  • Borzacchiello, Luigi
  • Gómez-Santos, Beatriz
  • Buqué, Xabier
  • Sáenz de Urturi, Diego
  • Gonzalez-Romero, Francisco
  • Simón, Jorge
  • Rodríguez-Agudo, Rubén
  • Ruiz, Asier
  • Matute, Carlos
  • Beiroa, Daniel
  • Falcón-Pérez, Juan M.
  • Aspichueta, Patricia
  • Rodríguez-Cuesta, Juan
  • Porcelli, Marina
  • Pajares, María Ángeles
  • Ameneiro, Cristina
  • Fidalgo, Miguel
  • Aransay, Ana M.
  • Lama-Diaz, Tomas
  • Blanco, Miguel G.
  • López, Miguel
  • Villa-Bellosta, Ricardo
  • Müller, Timo D.
  • Nogueiras, Rubén
  • Woodhoo, Ashwin
  • Tamayo-Caro, Miguel
  • Martínez-Chantar, María Luz
  • Varela-Rey, Marta
26 p.-6 fig.-1 tab.-1 graph. abst., There has been an intense focus to uncover the molecular mechanisms by which fasting triggers the adaptive cellular responses in the major organs of the body. Here, we show that in mice, hepatic S-adenosylmethionine (SAMe)—the principal methyl donor—acts as a metabolic sensor of nutrition to fine-tune the catabolic-fasting response by modulating phosphatidylethanolamine N-methyltransferase (PEMT) activity, endoplasmic reticulum-mitochondria contacts, β-oxidation, and ATP production in the liver, together with FGF21-mediated lipolysis and thermogenesis in adipose tissues. Notably, we show that glucagon induces the expression of the hepatic SAMe-synthesizing enzyme methionine adenosyltransferase α1 (MAT1A), which translocates to mitochondria-associated membranes. This leads to the production of this metabolite at these sites, which acts as a brake to prevent excessive β-oxidation and mitochondrial ATP synthesis and thereby endoplasmic reticulum stress and liver injury. This work provides important insights into the previously undescribed function of SAMe as a new arm of the metabolic adaptation to fasting., M.V.-R. is supported by Proyecto PID2020-119486RB-100 (funded by MCIN/AEI/10.13039/501100011033), Gilead Sciences International Research Scholars Program in Liver Disease, Acción Estratégica Ciberehd Emergentes 2018 (ISCIII), Fundación BBVA, HORIZON-TMA-MSCA-Doctoral Networks 2021 (101073094), and Redes de Investigación 2022 (RED2022-134485-T). M.L.M.-C. is supported by La CAIXA Foundation (LCF/PR/HP17/52190004), Proyecto PID2020-117116RB-I00 (funded by MCIN/AEI/10.13039/501100011033), Ayudas Fundación BBVA a equipos de investigación científica (Umbrella 2018), and AECC Scientific Foundation (Rare Cancers 2017). A.W. is supported by RTI2018-097503-B-I00 and PID2021-127169OB-I00, (funded by MCIN/AEI/10.13039/501100011033) and by “ERDF A way of making Europe,” Xunta de Galicia (Ayudas PRO-ERC), Fundación Mutua Madrileña, and European Community’s H2020 Framework Programme (ERC Consolidator grant no. 865157 and MSCA Doctoral Networks 2021 no. 101073094). C.M. is supported by CIBERNED. P.A. is supported by Ayudas para apoyar grupos de investigación del sistema Universitario Vasco (IT1476-22), PID2021-124425OB-I00 (funded by MCIN/AEI/10.13039/501100011033 and “ERDF A way of making Europe,” MCI/UE/ISCiii [PMP21/00080], and UPV/EHU [COLAB20/01]). M.F. and M.G.B. are supported by PID2019-105739GB-I00 and PID2020-115472GB-I00, respectively (funded by MCIN/AEI/10.13039/501100011033). M.G.B. is supported by Xunta de Galicia (ED431C 2019/013). C.A., T.L.-D., and J.B.-V. are recipients of pre-doctoral fellowships from Xunta de Galicia (ED481A-2020/046, ED481A-2018/042, and ED481A 2021/244, respectively). T.C.D. is supported by Fundación Científica AECC. A.T.-R. is a recipient of a pre-doctoral fellowship from Fundación Científica AECC. S.V.A. and C.R. are recipients of Margarita Salas postdoc grants under the “Plan de Recuperación Transformación” program funded by the Spanish Ministry of Universities with European Union’s NextGeneration EU funds (2021/PER/00020 and MU-21-UP2021-03071902373A, respectively). T.C.D., A.S.-R., and M.T.-C. are recipients of Ayuda RYC2020-029316-I, PRE2019/088960, and BES-2016/078493, respectively, supported by MCIN/AEI/10.13039/501100011033 and by El FSE invierte en tu futuro. S.L.-O. is a recipient of a pre-doctoral fellowship from the Departamento de Educación del Gobierno Vasco (PRE_2018_1_0372). P.A.-G. is recipient of a FPU pre-doctoral fellowship from the Ministry of Education (FPU19/02704). CIC bioGUNE is supported by Ayuda CEX2021-001136-S financiada por MCIN/AEI/10.13039/501100011033. A.B.-C. was funded by predoctoral contract PFIS (FI19/00240) from Instituto de Salud Carlos III (ISCIII) co-funded by Fondo Social Europeo (FSE), and A.D.-L. was funded by contract Juan Rodés (JR17/00016) from ISCIII. A.B.-C. is a Miguel Servet researcher (CPII22/00008) from ISCIII., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Nicotinamide N-methyltransferase (NNMT) regulates the glucocorticoid signaling pathway during the early phase of adipogenesis

  • Roberti, Annalisa
  • Tejedor, Juan Ramón
  • Díaz-Moreno, Irene
  • López, Virginia
  • Santamarina-Ojeda, Pablo
  • Pérez, Raúl F.
  • Urdinguio, Rocío G.
  • Concellón, Carmen
  • Martínez-Chantar, María Luz
  • Fernández-Morera, Juan L.
  • Díaz-Quintana, Antonio
  • Amo, Vicente del
  • Fernández, Agustín F.
  • Fraga, Mario F.
Obesity is associated with adipose tissue dysfunction through the differentiation and expansion of pre-adipocytes to adipocytes (hyperplasia) and/or increases in size of pre-existing adipocytes (hypertrophy). A cascade of transcriptional events coordinates the differentiation of pre-adipocytes into fully differentiated adipocytes; the process of adipogenesis. Although nicotinamide N-methyltransferase (NNMT) has been associated with obesity, how NNMT is regulated during adipogenesis, and the underlying regulatory mechanisms, remain undefined. In present study we used genetic and pharmacological approaches to elucidate the molecular signals driving NNMT activation and its role during adipogenesis. Firstly, we demonstrated that during the early phase of adipocyte differentiation NNMT is transactivated by CCAAT/Enhancer Binding Protein beta (CEBPB) in response to glucocorticoid (GC) induction. We found that Nnmt knockout, using CRISPR/Cas9 approach, impaired terminal adipogenesis by influencing the timing of cellular commitment and cell cycle exit during mitotic clonal expansion, as demonstrated by cell cycle analysis and RNA sequencing experiments. Biochemical and computational methods showed that a novel small molecule, called CC-410, stably binds to and highly specifically inhibits NNMT. CC-410 was, therefore, used to modulate protein activity during pre-adipocyte differentiation stages, demonstrating that, in line with the genetic approach, chemical inhibition of NNMT at the early stages of adipogenesis impairs terminal differentiation by deregulating the GC network. These congruent results conclusively demonstrate that NNMT is a key component of the GC-CEBP axis during the early stages of adipogenesis and could be a potential therapeutic target for both early-onset obesity and glucocorticoid-induced obesity., This work was supported by the Spanish Association Against Cancer (PROYE18061FERN to M.F.F.), the Asturias Government (PCTI) co-funding 2018-2023/FEDER (IDI/2018/146 and IDI/2021/000077 to M.F.F.), the Health Institute Carlos III (Plan Nacional de I+D+I) co-funding FEDER (PI18/01527 and PI21/01067 to M.F.F and A.F.F.), CIBERER Acciones Cooperativas y Complementarias Intramurales (ACCI20-35 to M.F.F.), the Fundación General CSIC (0348_CIE_6_E to M.F.F.), the ISCIII (COV00624 to J.R.T. and M.F.F.), ISPA and the Asociación Galbán (2021-052-INTRAMUR GALBAN-GOURR to R.G.U.), ISPA-Jannsen (2021-048-INTRAMURAL NOV-TEVAR to J.R.T.), CSIC (202020E092 to M.F.F), and the European Commission NextGenerationEU, through CSIC’s Global Health Platform (PTI Salud Global) and the Spanish Ministry of Science and Innovation through the Recovery, Transformation and Resilience Plan (SGL2021-03-39 and SGL2021-03-040). The authors are also grateful to the Spanish Ministry of Science and Innovation (PID2021-126663NB-100; CTQ2016-76829-R; PID2020-113473GB-I00), the Regional Government of Andalusia (BIO198 and P18-FR-3487) and the Ramón Areces Foundation (2021-2024). A.R. is supported by CSIC (SOLAUT_00038505 SGL2103040). J.R.T. is supported by a Juan de la Cierva fellowship from the Spanish Ministry of Science and Innovation MCIN/AEI/https://doi.org/10.13039/501100011033 (IJC2018-036825-I). R.F.P. (BP17-114) and P.S.M. (BP17-165) are supported by the Severo Ochoa program. R.G.U. is supported by the Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER). M.L.M.-C is supported by grants from Ministerio de Ciencia, Innovación y Universidades (MICINN) PID2020-117116RB-I00 integrated in Plan Estatal de Investigación Científica y Técnica y Innovación (to M.L.M.-C), and co-funded with Fondos FEDER (to M.L.M.-C), Subprograma Retos Colaboración RTC2019-007125-1 (to M.L.M.-C), La Caixa Foundation Program HR17-00601 (to MLM-C), Proyectos Investigación en Salud DTS20/00138 (to M.L.M.-C), Departamento de Industria del Gobierno Vasco (to M.L.M.-C), Elkartek (KK-2020/00008) (to M.L.M.-C). We also acknowledge support from the Institute of Oncology of Asturias (IUOPA, supported by Obra Social Cajastur Liberbank, Spain), the Health Research Institute of Asturias (ISPA-FINBA) and Consorcio Centro de Investigación Biomédica en Red (CIBERER-ISCIII)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The outcome of boosting mitochondrial activity in alcohol-associated liver disease is organ-dependent

  • Goikoetxea-Usandizaga, Naroa
  • Bravo, Miren
  • Egia-Mendikute, Leire
  • Abecia, Leticia
  • Serrano-Maciá, Marina
  • Urdinguio, Rocío G.
  • Clos-García, Marc
  • Rodríguez-Agudo, Rubén
  • Araujo-Legido, Raquel
  • López-Bermudo, Lucía
  • Delgado, Teresa C.
  • Lachiondo-Ortega, Sofía
  • González-Recio, Irene
  • Gil-Pitarch, Clàudia
  • Peña-Cearra, Ainize
  • Simón, Jorge
  • Benedé-Ubieto, Raquel
  • Ariño, Silvia
  • Herranz, Jose M.
  • Azkargorta, Mikel
  • Salazar-Bermeo, Julio
  • Martí, Nuria
  • Varela-Rey, Marta
  • Falcón-Pérez, Juan M.
  • Lorenzo, Óscar
  • Nogueiras, Rubén
  • Elortza, Félix
  • Nevzorova, Yulia
  • Cubero, Francisco J.
  • Saura, Domingo
  • Martínez-Cruz, Luis Alfonso
  • Sabio, Guadalupe
  • Palazón, Asís
  • Palazón, Asís
  • Sancho-Bru, Pau
  • Elguezabal, Natalia
  • Fraga, Mario F.
  • Ávila, Matías A.
  • Bataller, Ramón
  • Marín, José J. G.
  • Martín, Franz
  • Martínez-Chantar, María Luz
Background and Aims: Alcohol-associated liver disease (ALD) accounts for 70% of liver-related deaths in Europe, with no effective approved therapies. Although mitochondrial dysfunction is one of the earliest manifestations of alcohol-induced injury, restoring mitochondrial activity remains a problematic strategy due to oxidative stress. Here, we identify methylation-controlled J protein (MCJ) as a mediator for ALD progression and hypothesize that targeting MCJ may help in recovering mitochondrial fitness without collateral oxidative damage. Approach and Results: C57BL/6 mice [wild-type (Wt)] Mcj knockout and Mcj liver-specific silencing (MCJ-LSS) underwent the NIAAA dietary protocol (Lieber-DeCarli diet containing 5% (vol/vol) ethanol for 10 days, plus a single binge ethanol feeding at day 11). To evaluate the impact of a restored mitochondrial activity in ALD, the liver, gut, and pancreas were characterized, focusing on lipid metabolism, glucose homeostasis, intestinal permeability, and microbiota composition. MCJ, a protein acting as an endogenous negative regulator of mitochondrial respiration, is downregulated in the early stages of ALD and increases with the severity of the disease. Whole-body deficiency of MCJ is detrimental during ALD because it exacerbates the systemic effects of alcohol abuse through altered intestinal permeability, increased endotoxemia, and dysregulation of pancreatic function, which overall worsens liver injury. On the other hand, liver-specific Mcj silencing prevents main ALD hallmarks, that is, mitochondrial dysfunction, steatosis, inflammation, and oxidative stress, as it restores the NAD+/NADH ratio and SIRT1 function, hence preventing de novo lipogenesis and improving lipid oxidation. Conclusions: Improving mitochondrial respiration by liver-specific Mcj silencing might become a novel therapeutic approach for treating ALD., This work was supported by grants from Ministerio de Ciencia e Innovación, Programa Retos-Colaboración RTC2019-007125-1 (for Jorge Simon and Maria Luz Martinez-Chantar); Ministerio de Economía, Industria y Competitividad, Retos a la Sociedad AGL2017- 86927R (for F.M.); Instituto de Salud Carlos III, Proyectos de Investigación en Salud DTS20/00138 and DTS21/00094 (for Jorge Simon and Maria Luz Martinez-Chantar, and Asis Palazon. respectively); Instituto de Salud Carlos III, Fondo de Investigaciones Sanitarias co-founded by European Regional Development Fund/European Social Fund, “Investing in your future” PI19/00819, “Una manera de hacer Europa” FIS PI20/00765, and PI21/01067 (for Jose J. G. Marin., Pau Sancho-Bru,. and Mario F. Fraga respectively); Departamento de Industria del Gobierno Vasco (for Maria Luz Martinez-Chantar); Asturias Government (PCTI) co-funding 2018-2023/ FEDER IDI/2021/000077 (for Mario F. Fraga.); Ministerio de Ciencia, Innovación y Universidades MICINN: PID2020-117116RB-I00, CEX2021-001136-S PID2020-117941RB-I00, PID2020-11827RB-I00 and PID2019-107956RA-100 integrado en el Plan Estatal de Investigación Científica y Técnica y Innovación, cofinanciado con Fondos FEDER (for Maria Luz Martinez- Chantar, Francisco J Cubero., Yulia A Nevzorova and Asis Palazon); Ayudas Ramón y Cajal de la Agencia Estatal de Investigación RY2013-13666 and RYC2018- 024183-I (for Leticia Abecia and Asis Palazon); European Research Council Starting Grant 804236 NEXTGEN- IO (for Asis Palazon); The German Research Foundation SFB/TRR57/P04, SFB1382-403224013/ A02 and DFG NE 2128/2-1 (for Francisco J Cubero and Yulia A Nevzorova); National Institute of Health (NIH)/National Institute of Alcohol Abuse and Alcoholism (NIAAA) 1U01AA026972-01 (For Pau Sancho-Bru); Junta de Castilla y León SA074P20 (for Jose J. G. Marin); Junta de Andalucía, Grupo PAIDI BIO311 (for Franz Martin); CIBERER Acciones Cooperativas y Complementarias Intramurales ACCI20-35 (for Mario F. Fraga); Ministerio de Educación, Cultura y Deporte FPU17/04992 (for Silvia Ariño); Fundació Marato TV3 201916-31 (for Jose J. G. Marin.); Ainize Pena-Cearra is a fellow of the University of the Basque Country (UPV/ EHU); BIOEF (Basque Foundation for Innovation and Health Research); Asociación Española contra el Cáncer (Maria Luz Martinez-Chantar and Teresa C. Delgado.); Fundación Científica de la Asociación Española Contra el Cáncer (AECC Scientific Foundation) Rare Tumor Calls 2017 (for Maria Luz Martinez-Chantar); La Caixa Foundation Program (for Maria Luz Martinez-Chantar); Proyecto Desarrollo Tecnologico CIBERehd (for Maria Luz Martinez-Chantar); Ciberehd_ISCIII_MINECO is funded by the Instituto de Salud Carlos III., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Exogenous aralar/slc25a12 can replace citrin/slc25a13 as malate aspartate shuttle component in liver

  • González-Moreno, Luis
  • Santamaría-Cano, Andrea
  • Paradela, Alberto
  • Martínez-Chantar, María Luz
  • Martín, Miguel Á
  • Pérez-Carreras, Mercedes
  • García-Picazo, Alberto
  • Vázquez, Jesús
  • Calvo, Enrique
  • González-Aseguinolaza, Gloria
  • Saheki, Takeyori
  • Del Arco, Araceli
  • Satrústegui, Jorgina
  • Contreras, Laura
The deficiency of CITRIN, the liver mitochondrial aspartate–glutamate carrier (AGC), is the cause of four human clinical phenotypes, neonatal intrahepatic cholestasis caused by CITRIN deficiency (NICCD), silent period, failure to thrive and dyslipidemia caused by CITRIN deficiency (FTTDCD), and citrullinemia type II (CTLN2). Clinical symptoms can be traced back to disruption of the malate-aspartate shuttle due to the lack of citrin. A potential therapy for this condition is the expression of aralar, the AGC present in brain, to replace citrin. To explore this possibility we have first verified that the NADH/NAD ratio increases in hepatocytes from citrin(−/−) mice, and then found that exogenous aralar expression reversed the increase in NADH/NAD observed in these cells. Liver mitochondria from citrin (−/−) mice expressing liver specific transgenic aralar had a small (~ 4–6 nmoles x mg prot x min) but consistent increase in malate aspartate shuttle (MAS) activity over that of citrin(−/−) mice. These results support the functional replacement between AGCs in the liver. To explore the significance of AGC replacement in human therapy we studied the relative levels of citrin and aralar in mouse and human liver through absolute quantification proteomics. We report that mouse liver has relatively high aralar levels (citrin/aralar molar ratio of 7.8), whereas human liver is virtually devoid of aralar (CITRIN/ARALAR ratio of 397). This large difference in endogenous aralar levels partly explains the high residual MAS activity in liver of citrin(−/−) mice and why they fail to recapitulate the human disease, but supports the benefit of increasing aralar expression to improve the redox balance capacity of human liver, as an effective therapy for CITRIN deficiency., This work was supported by the CITRIN FOUNDATION, in Singapore founded by Barbara Yu Fa and Yen How Tai (to J.S.), by MICINN [grant PID2020-114499RB-I00 AEI/FEDER, UE, to A. del A.], by Instituto de Investigación Hospital 12 de Octubre (Imas12), Madrid, Spain [grant 2019/0039 to M.P.-C.] by Ministerio de Ciencia, Innovación y Universidades MICINN [grant PID2020-117116RB-I00 in “Plan Estatal de Investigación Cientifica y Técnica y Innovación, cofinanciado con Fondos FEDER (to M.L.M.-C.]; by La Caixa Foundation Program (to M.L.M.-C.), by Programa Retos [RTC2019-007125-1, to M.L.M.-C.)], Proyectos Investigacion en Salud [DTS20/00138 to M.L.M.-C.], and by institutional grant from Fundación Areces to the Centro de Biología Molecular Severo Ochoa. L.G.-M. was recipient of predoctoral fellowship from MINECO and A.S.-C. was recipient of a predoctoral research contract from Comunidad de Madrid
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Neddylation of phosphoenolpyruvate carboxykinase 1 controls glucose metabolism

  • Gonzalez-Rellan, María J
  • Fernández, Uxía
  • Parracho, Tamara
  • Novoa, Eva
  • Fondevila, Marcos F
  • da Silva Lima, Natalia
  • Ramos, Lucía
  • Rodríguez, Amaia
  • Serrano-Maciá, Marina
  • Pérez-Mejías, Gonzalo
  • Chantada-Vazquez, Pilar
  • Riobello, Cristina
  • Veyrat-Durebex, Christelle
  • Tovar, Sulay
  • Coppari, Roberto
  • Woodhoo, Ashwin
  • Schwaninger, Markus
  • Prevot, Vincent
  • Delgado, Teresa C.
  • Lopez, Miguel
  • Díaz-Quintana, Antonio
  • Dieguez, Carlos
  • Guallar, Diana
  • Frühbeck, Gema
  • Díaz-Moreno, Irene
  • Bravo, Susana B
  • Martinez-Chantar, Maria L
  • Nogueiras, Ruben
Neddylation is a post-translational mechanism that adds a ubiquitin-like protein, namely neural precursor cell expressed developmentally downregulated protein 8 (NEDD8). Here, we show that neddylation in mouse liver is modulated by nutrient availability. Inhibition of neddylation in mouse liver reduces gluconeogenic capacity and the hyperglycemic actions of counter-regulatory hormones. Furthermore, people with type 2 diabetes display elevated hepatic neddylation levels. Mechanistically, fasting or caloric restriction of mice leads to neddylation of phosphoenolpyruvate carboxykinase 1 (PCK1) at three lysine residues-K278, K342, and K387. We find that mutating the three PCK1 lysines that are neddylated reduces their gluconeogenic activity rate. Molecular dynamics simulations show that neddylation of PCK1 could re-position two loops surrounding the catalytic center into an open configuration, rendering the catalytic center more accessible. Our study reveals that neddylation of PCK1 provides a finely tuned mechanism of controlling glucose metabolism by linking whole nutrient availability to metabolic homeostasis., This work was supported by grants from: FEDER/Ministerio de Ciencia, Innovación y Universidades-Agencia Estatal de Investigación (M.L.M.-C.: PID2020-117116RB-I00; C.D.: BFU2017-87721; M.L.: RTI2018-101840-B-I00; R.N.: PID2021-126096NB-I00 and RED2018-102379-T); Xunta de Galicia (R.N.: 2021-CP085 and 2020-PG0157); Fundación BBVA (to R.N.); Subprograma Retos Colaboración RTC2019-007125-1 (to M.L.M.-C.); Proyectos Investigación en Salud DTS20/00138 (to M.L.M.-C.); Proyectos Investigación en Salud (M.L.M.-C.: DTS20/00138); Fundación Atresmedia (to M.L. and R.N.); and Fundación La Caixa (to M.L., M.L.M.-C., and R.N.). This research also received funding from the European Community’s H2020 Framework Programme (ERC Synergy Grant-2019-WATCH- 810331, to R.N., V.P., and M.S.). The Centro de Investigación Biomédica en Red (CIBER) de Fisiopatología de la Obesidad y Nutrición (CIBERobn) and the Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Hepáticas y Digestivas (CIBERehd) are initiatives of the Instituto de Salud Carlos III (ISCIII) of Spain, which is supported by FEDER funds. We thank MINECO for the Severo Ochoa Excellence Accreditation bioGUNE (SEV-2016-0644) to CIC., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Anti-miR-873-5p improves alcohol-related liver disease by enhancing hepatic deacetylation via SIRT1

  • Rodríguez-Agudo, Rubén
  • González-Recio, Irene
  • Serrano-Maciá, Marina
  • Bravo, Miren
  • Petrov, Petar D.
  • Blaya, Delia
  • Herranz, José María
  • Mercado-Gómez, María
  • Rejano-Gordillo, Claudia María
  • Lachiondo-Ortega, Sofía
  • Gil-Pitarch, Clàudia
  • Azkargorta, Mikel
  • Liempd, Sebastiaan Martijn van
  • Martínez-Cruz, Luis Alfonso
  • Simão, A. L.
  • Elortza, Félix
  • Martín, César
  • Nevzorova, Yulia A.
  • Cubero, Francisco Javier
  • Delgado, Teresa C.
  • Argemi, Josepmaria
  • Bataller, Ramón
  • Schoonjans, Kristina
  • Banales, Jesús M.
  • Castro, Rui E.
  • Sancho-Bru, Pau
  • Ávila, Matías A.
  • Julve, Josep
  • Jover, Ramiro
  • Mabe, Jon
  • Simón, Jorge
  • Goikoetxea-Usandizaga, Naroa
  • Martínez-Chantar, María Luz
© 2023 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL). This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)., [Background & Aims] Current therapies for the treatment of alcohol-related liver disease (ALD) have proven largely ineffective. Patients relapse and the disease progresses even after liver transplantation. Altered epigenetic mechanisms are characteristic of alcohol metabolism given excessive acetate and NAD depletion and play an important role in liver injury. In this regard, novel therapeutic approaches based on epigenetic modulators are increasingly proposed. MicroRNAs, epigenetic modulators acting at the post-transcriptional level, appear to be promising new targets for the treatment of ALD., [Methods] MiR-873-5p levels were measured in 23 liver tissue from Patients with ALD, and GNMT levels during ALD were confirmed using expression databases (transcriptome n = 62, proteome n = 68). High-resolution proteomics and metabolomics in mice following the Gao-binge model were used to investigate miR-873-5p expression in ALD. Hepatocytes exposed to 50 mM alcohol for 12 h were used to study toxicity. The effect of anti-miR-873-5p in the treatment outcomes of ALD was investigated., [Results] The analysis of human and preclinical ALD samples revealed increased expression of miR-873-5p in the liver. Interestingly, there was an inverse correlation with NNMT, suggesting a novel mechanism for NAD depletion and aberrant acetylation during ALD progression. High-resolution proteomics and metabolomics identified miR-873-5p as a key regulator of NAD metabolism and SIRT1 deacetylase activity. Anti-miR-873-5p reduced NNMT activity, fuelled the NAD salvage pathway, restored the acetylome, and modulated the levels of NF-κB and FXR, two known SIRT1 substrates, thereby protecting the liver from apoptotic and inflammatory processes, and improving bile acid homeostasis., [Conclusions] These data indicate that targeting miR-873-5p, a repressor of GNMT previously associated with NAFLD and acetaminophen-induced liver failure. is a novel and attractive approach to treating alcohol-induced hepatoxicity., [Impact and implications] The role of miR-873-5p has not been explicitly examined in the progression of ALD, a pathology with no therapeutic options. In this study, inhibiting miR-873-5p exerted hepatoprotective effects against ALD through rescued SIRT1 activity and consequently restored bile acid homeostasis and attenuated the inflammatory response. Targeting hepatic miR-873-5p may represent a novel therapeutic approach for the treatment of ALD., With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2021-001136-S)., This work was supported by grants from Ministerio de Ciência, Innovación y Universidades MICINN: PID2020-117116RB-I00 CEX2021-001136-S integrado en el Plan Estatal de Investigación Científica y Técnica e Innovación, cofinanciado con Fondos FEDER (to MLM-C); Ministerio de Ciência e Innovación, Programa Retos-Colaboración RTC2019-007125-1 (to MLM-C); Instituto de Salud Carlos III, Proyectos Investigación en Salud DTS20/00138 (to MLM-C); La Caixa Scientific Foundation (HR17-00601) (for REC, MLM-C and JMB); La Caixa Consortium (to JMB, REC, KS and MLM-C); Instituto de Salud Carlos III, Fondo de Investigaciones Sanitarias co-founded by the European Union, PI20/00690, PI20/00765, PI20/01663 and PI21/00922 (to RJ, PS-B, JA and JMB respectively); Miguel Servet Programme CPII19/00008 (to JMB); AMMF-The Cholangiocarcinoma Charity (EU/2019/AMMFt/001) (to JMB); PSC Partners US and PSC Supports UK 06119JB (to JMB); European Union’s Horizon 2020 Research and Innovation Program, 825510 (for JMB) Ministerio de Sanidad y Consumo, Instituto de Salud Carlos III (Madrid, Spain) grant PI21/00770 (for JJ), Fundação para a Ciência e a Tecnologia (grants PTDC/MED-PAT/31882/2017 and EXPL/MED-OUT/1317/2021 to REC and ALS)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

New insights into the regulation of bile acids synthesis during the early stages of liver regeneration: A human and experimental study

  • Uriarte, Iker
  • Santamaría, Eva
  • López-Pascual, Amaya
  • Monte, María J.
  • Argemí, Josepmaria
  • Latasa, M. Ujue
  • Adán-Villaescusa, Elena
  • Irigaray, Ainara
  • Herranz, José M.
  • Arechederra, María
  • Basualdo, Jorge
  • Lucena, Felipe
  • Corrales, Fernando J.
  • Rotellar, Fernando
  • Pardo, Fernando
  • Merlen, Gregory
  • Rainteau, Dominique
  • Sangro, Bruno
  • Tordjmann, Thierry
  • Berasain, Carmen
  • Marín, José J. G.
  • Fernández-Barrena, Maite G.
  • Herrero, Ignacio
  • Avila, Matias A.
Background and aims: Liver regeneration is essential for the preservation of homeostasis and survival. Bile acids (BAs)-mediated signaling is necessary for liver regeneration, but BAs levels need to be carefully controlled to avoid hepatotoxicity. We studied the early response of the BAs-fibroblast growth factor 19 (FGF19) axis in healthy individuals undergoing hepatectomy for living donor liver transplant. We also evaluated BAs synthesis in mice upon partial hepatectomy (PH) and acute inflammation, focusing on the regulation of cytochrome-7A1 (CYP7A1), a key enzyme in BAs synthesis from cholesterol. Methods: Serum was obtained from twelve human liver donors. Mice underwent 2/3-PH or sham-operation. Acute inflammation was induced with bacterial lipopolysaccharide (LPS) in mice fed control or antoxidant-supplemented diets. BAs and 7α-hydroxy-4-cholesten-3-one (C4) levels were measured by HPLC-MS/MS; serum FGF19 by ELISA. Gene expression and protein levels were analyzed by RT-qPCR and western-blot. Results: Serum BAs levels increased after PH. In patients with more pronounced hypercholanemia, FGF19 concentrations transiently rose, while C4 levels (a readout of CYP7A1 activity) dropped 2 h post-resection in all cases. Serum BAs and C4 followed the same pattern in mice 1 h after PH, but C4 levels also dropped in sham-operated and LPS-treated animals, without marked changes in CYP7A1 protein levels. LPS-induced serum C4 decline was attenuated in mice fed an antioxidant-supplemented diet. Conclusions: In human liver regeneration FGF19 upregulation may constitute a protective response from BAs excess during liver regeneration. Our findings suggest the existence of post-translational mechanisms regulating CYP7A1 activity, and therefore BAs synthesis, independent from CYP7A1/Cyp7a1 gene transcription., This work was supported by grants from Ministerio de Ciencia, Innovación y Universidades MICINN-Agencia Estatal de Investigación integrado en el Plan Estatal de Investigación Científica y Técnica y Innovación, cofinanciado con Fondos FEDER PID2022-136616OB-I00 (MAA), PID2020-117116RB-I00 (MGFB), PID2021-127496NB-100 (FJC). Fondo de Investigaciones Sanitarias, Instituto de Salud Carlos III, Spain (PI14/01442 to FL and PI22/00526 to JJGM) co-funded by European Regional Development Fund/European Social Fund, “Investing in your future” (FL). Fundació Marato TV3 (Ref. 201916-31) (JJGM). INSERM and Agence National de la Recherche (ANR) grant 15-CE14-0007 (TT and GM). AECC post-doctoral fellowship POSTD18014AREC to MA. Ramón y Cajal Program contract RYC2018-024475-1 (MGFB) from the Spanish Ministry of Science and Innovation. Sara Borrell Contract CD22/00109 from the Spanish Ministry of Health (A.L-P.). AECC Undergraduate research fellowship PPLAB235506IRIG (A.I.). Grants from Fundación Mario Losantos and Fundación M Torres (MAA, CB, MGFB)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

SUMOylation controls Hu antigen R posttranscriptional activity in liver cancer

  • Lachiondo-Ortega, Sofía
  • Rejano-Gordillo, Claudia María
  • Simón, Jorge
  • Lopitz-Otsoa, Fernando
  • Delgado, Teresa C.
  • Mazan-Mamczarz, Krystyna
  • Goikoetxea-Usandizaga, Naroa
  • Zapata-Pavas, L. Estefanía
  • García-del Río, Ana
  • Guerra, Pietro
  • Peña-Sanfélix, Patricia
  • Hermán-Sánchez, Natalia
  • Al-Abdulla, Ruba
  • Fernández-Rodríguez, Carmen
  • Azkargorta, Mikel
  • Velázquez-Cruz, Alejandro
  • Guyon, Joris
  • Martín, César
  • Zalamea, Juan Diego
  • Egia-Mendikute, Leire
  • Sanz-Parra, Arantza
  • Serrano-Maciá, Marina
  • González-Recio, Irene
  • Gonzalez-López, Monika
  • Martínez-Cruz, Luis Alfonso
  • Pontisso, Patrizia
  • Aransay, Ana M.
  • Barrio, Rosa
  • Sutherland, James D.
  • Abrescia, Nicola G. A.
  • Elortza, Félix
  • Lujambio, Amaia
  • Banales, Jesús M.
  • Luque, Raúl M.
  • Gahete, Manuel D.
  • Palazón, Asís
  • Ávila, Matías A.
  • Marín, José J. G.
  • De, Supriyo
  • Daubon, Thomas
  • Diaz-Quintana, Antonio
  • Díaz-Moreno, Irene
  • Gorospe, Myriam
  • Rodríguez, Manuel S.
  • Martínez-Chantar, María Luz
© 2024 The Author(s). This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)., The posttranslational modification of proteins critically influences many biological processes and is a key mechanism that regulates the function of the RNA-binding protein Hu antigen R (HuR), a hub in liver cancer. Here, we show that HuR is SUMOylated in the tumor sections of patients with hepatocellular carcinoma in contrast to the surrounding tissue, as well as in human cell line and mouse models of the disease. SUMOylation of HuR promotes major cancer hallmarks, namely proliferation and invasion, whereas the absence of HuR SUMOylation results in a senescent phenotype with dysfunctional mitochondria and endoplasmic reticulum. Mechanistically, SUMOylation induces a structural rearrangement of the RNA recognition motifs that modulates HuR binding affinity to its target RNAs, further modifying the transcriptomic profile toward hepatic tumor progression. Overall, SUMOylation constitutes a mechanism of HuR regulation that could be potentially exploited as a therapeutic strategy for liver cancer., This work was supported by grants to M.L.M.-C. from Departamento de Industria del Gobierno Vasco, Spain; Ministerio de Ciencia e Innovación, Spain (grant no. PID2020-117116RB-I00); European Regional Development Fund (ERDF), EU; and CIBERehd, which is funded by Instituto de Salud Carlos III (ISCIII), Spain. M.L.M.-C. and J.S. received funding from Ministerio de Ciencia e Innovación (grant no. RTC2019-007125-1) and ISCIII (grant no. DTS20/00138). M.L.M.-C. and R.M.L. acknowledge Ministerio de Ciencia e Innovación (grant no. RED2022-134397-T). M.L.M.-C. and J.M.B. were awarded with a grant from Fundación la Caixa, Spain (grant no. HR17-00601). M.L.M.-C., J.M.B., M.A.A., and J.J.G.M. acknowledge financial support from Fundación Científica de la Asociación Española Contra el Cáncer (AECC), Spain. M.S.R. recognizes funding from Fondo Sectorial de Investigación SRE - CONACYT, Mexico (grant no. 0280365); Horizon 2020 Research and Innovation Program funded under Marie Skłodowska-Curie Actions, EU (grant no. 765445); and REPÈRE and Programme de Prématuration from Région Occitanie, France. M.G., S.D., and K.M.-M. were supported by the National Institute on Aging (NIA), National Institutes of Health (NIH), US (grant no. Z01-AG000511-23). I.D.-M. is grateful for the grants received from Junta de Andalucía, Spain (grant no. BIO-198, US-1254317, P18-FR-3487, and P18-HO-4091); Ministerio de Ciencia, Innovación y Universidades, Spain (grant no. PGC2018-096049-BI00); and Fundación Ramón Areces, Spain. T.D. acknowledges Fondation ARC, France (grant no. 208084). J.J.G.M. was supported by Junta de Castilla y León, Spain (grant no. SA063P17); Fundación La Marató TV3, Spain (grant no. 201916-31); ISCIII (grant no. PI19/00819); CIBERehd; and ERDF (grant no. OLD-HEPAMARKER). M.A.A. recognizes Gobierno de Navarra, Spain (grant no. GºNa 42/21); Eurorregión Nueva Aquitania-Euskadi-Navarra, Spain; Ministerio de Ciencia e Innovación (grant no. PID2019-104878RB-I00); and CIBERehd. A.P. expresses gratitude to the European Research Council (ERC), EU (grant no. 804236) for their support. M.D.G. received financial support from Junta de Andalucía (grant no. PEMP-0036-2020 and BIO-0139); Ministerio de Universidades, Spain (grant no. FPU20/03957); ISCIII (grant no. PI20/01301), Fundación Sociedad Española de Endocrinología y Nutrición (FSEEN), Spain; CIBERehd; and CIBERobn, which is also funded by ISCIII. J.M.B. acknowledges Euskadi RIS3 (grant no. 2019222054, 2020333010, and 2021333003) and Elkartek programs from Gobierno Vasco (grant no. KK-2020/00008); ISCIII (grant no. PI18/01075, CPII19/00008, and PI21/00922); CIBERehd; PSC Support, UK; AMMF The Cholangiocarcinoma Charity, UK (grant no. EU/2019/AMMFt/001); Horizon 2020 Research and Innovation Program (grant no. 825510); ERDF; and PSC Partners Seeking a Cure, US. A.L. received financial support from the Damon Runyon-Rachleff Innovation Award, US (grant no. DR52-18) and the MERIT Award (R37) from the National Cancer Institute (NCI), NIH (grant no. R37CA230636). F.E. expresses his gratitude to ProteoRed from ISCIII (grant no. PT13/0001/0027) and CIBERehd. N.G.A.A. was funded by Ministerio de Ciencia, Innovación y Universidades (grant no. RTI2018-095700-B-I00). R.B. acknowledges financial support from Gobierno Vasco (grant no. IT1165-19); Ministerio de Economía, Industria y Competitividad, Spain (grant no. SAF2017-90900-REDT); Ministerio de Economía, Industria y Competitividad, ERDF (grant no. BFU2017-84653-P); Ministerio de Ciencia e Innovación (grant no. PID2020-114178GB-I00); and Horizon 2020 funded under Marie Skłodowska-Curie Actions (grant no. 765445-EU). A.M.A. acknowledges CIBERehd. L.A.M.-C. obtained grants from Ministerio de Economía y Competitividad (grant no. CSD2008-00005); Ministerio de Economía, Industria y Competitividad (grant no. BFU2016-77408-R); ISCIII; and EJP RD, EU (grant no. EJPRD19-040). I.G.-R. was supported by Ministerio de Economía, Industria y Competitividad (grant no. BES-2017-080435 ). M.S.-M. is grateful to the AECC, Sede de Bizkaia, Spain for the financial support. J.D.Z. was awarded with a grant from Ministerio de Economía, Industria y Competitividad (grant no. SEV-2016-0644-18-2). C.M. acknowledges Gobierno Vasco (grant no. IT-1264-19) and Ministerio de Ciencia e Innovación (grant no. PID2022-136788OB-I00). A.V.-C. was supported by Ministerio de Educación, Cultura y Deporte, Spain (grant no. FPU016/01513). C.F.-R. thanks Tekniker, Spain and CIC bioGUNE, Spain for financial support. A.G.-d.R. was funded by Bikaintek program from Gobierno Vasco (grant no. 48-AF-W1-2019-00012). N.G.-U. obtained a grant from Gobierno Vasco. T.C.D. expresses gratitude to AECC. J.S. received financial support from CIBERehd. C.M.R.-G. was supported by Ayudas a la Recualificación Margarita Salas from Universidad de Extremadura, Ministerio de Universidades financed by NextGenerationEU., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Identification and experimental validation of druggable epigenetic targets in hepatoblastoma

  • Clavería-Cabello, Alex
  • Herranz, Jose Maria
  • Latasa, Maria Ujue
  • Arechederra, Maria
  • Uriarte, Iker
  • Pineda-Lucena, Antonio
  • Prosper, Felipe
  • Berraondo, Pedro
  • Alonso, Cristina
  • Sangro, Bruno
  • García Marin, Jose Juan
  • Martinez-Chantar, Maria Luz
  • Ciordia, Sergio
  • Corrales, Fernando J.
  • Francalanci, Paola
  • Alaggio, Rita
  • Zucman-Rossi, Jessica
  • Indersie, Emilie
  • Cairo, Stefano
  • Domingo-Sàbat, Montserrat
  • Zanatto, Laura
  • Sancho-Bru, Pau
  • Armengol, Carolina
  • Berasain, Carmen
  • Fernández-Barrena, Maite G.
  • Ávila, Matias Antonio
Supplementary data to this article can be found online at https://doi.org/10.1016/ j.jhep.2023.05.031, Hepatoblastoma (HB) is the most frequent childhood liver cancer. Patients with aggressive tumors have limited therapeutic options; therefore, a better understanding of HB pathogenesis is needed to improve treatment. HBs have a very low mutational burden; however, epigenetic alterations are increasingly recognized. We aimed to identify epigenetic regulators consistently dysregulated in HB and to evaluate the therapeutic efficacy of their targeting in clinically relevant models., This work was supported by grants from the Scientific Foundation of the Spanish Association Against Cancer (AECC) LABAE20011GARC (MGFB), PROYE19044SANC (PSB), and Innova-INNOV211822SANJ (FP). Grants from Ministerio de Ciencia, Innovación y Universidades MICINN-Agencia Estatal de Investigación integrado en el Plan Estatal de Investigación Científica y Técnica y Innovación, cofinanciado con Fondos FEDER PID2019-104878RB-100/AEI/10.13039/501100011033 (MAA), PID2020-117116RB-I00 (MGFB), PID2021-127496NB-100 (FJC), PID2020-115875RB-100/AEI/10.13039/501100011033 (APL), and PID2020-117116RB-I00 (MLMC). Intramural CSIC PIE/COVID-19 projects 202020E079 and 202020E108; Comunidad de Madrid Grant B2017/BMD-3817; Severo Ochoa Project SEV 2017-0712; European Commission-NextGenerationEU (Regulation EU 2020/2094), through CSIC’s Global Health Platform (PTI Salud Global) (FJC). Instituto de Salud Carlos III (ISCIII) CIBERONC CB16/12/00489 (FP). Navarra Government Department of Health (44/2021) (also co-financed by FEDER) and Department of Economic Development AGATA (0011-1411-2020-000011 and 0011-1411-2020-000010) (FP). Fondo de Investigaciones Sanitarias, Instituto de Salud Carlos III, Spain (PI19/00819 and PI22/00526 co-funded by European Regional Development Fund/European Social Fund, “Investing in your future”); Junta de Castilla y Leon (SA074P20) and Fundació Marato TV3 (Ref. 201916/31) (JJGM). European Union's Horizon 2020 research and innovation program under grant agreement N° 668596 (ChiLTERN) and N° 826121 (iPC) and AGAUR (2017-SGR-490) (CA). Ligue contre le cancer (équipe labellisée), SFCE (Société Française de Lutte Contre les Cancers et les Leucémies de l’Enfant), the SIRIC CARPEM, PeLiCan.Resist InCa (Pediatric LIver CANcer database to combat RESISTance to treatment, Institut National du Cancer), France Génomique, association Etoile de Martin, Fédération Enfants et Santé, association Hubert Gouin “Enfance et Cancer,” INSERM Plan Cancer (JZR). FIMA pre-doctoral fellowship to ACC, AECC post-doctoral fellowship POSTD18014AREC to MA and Ramón y Cajal Program contracts RYC-2010-07249 (CA) and RYC2018-024475-1 (MGFB) from the Spanish Ministry of Science and Innovation. This work was supported by a grant (PRYCO223102ARME) from the Scientific Foundation of the AECC (CA, MAA, MLMC, PSB, JJGM), grant EDH22PI01 from CIBERehd (CA, MAA, JJGM, PB). Grants from Fundación Eugenio Rodríguez Pascual; Fundación Echébano; Fundación Mario Losantos, Fundación M Torres (MAA, CB, MGFB)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The lipopolysaccharide-TLR4 axis regulates hepatic glutaminase 1 expression promoting liver ammonia build-up as steatotic liver disease progresses to steatohepatitis

  • Mercado-Gómez, Maria
  • Goikoetxea-Usandizaga, Naroa
  • Kerbert, Annarein J.C.
  • Uraga Gracianteparaluceta, Leire
  • Serrano-Maciá, Marina
  • Lachiondo-Ortega, Sofía
  • Rodríguez-Agudo, Rubén
  • Gil-Pitarch, Clàudia
  • Simón, Jorge
  • González-Recio, Irene
  • Fondevila, Marcos F.
  • Santamarina-Ojeda, Pablo
  • Fraga, Mario F.
  • Nogueiras, Rubén
  • Heras, Javier de las
  • Jalan, Rajiv
  • Martínez-Chantar, María Luz
  • Delgado, Teresa C.
[Introduction]: Ammonia is a pathogenic factor implicated in the progression of metabolic-associated steatotic liver disease (MASLD). The contribution of the glutaminase 1 (GLS) isoform, an enzyme converting glutamine to glutamate and ammonia, to hepatic ammonia build-up and the mechanisms underlying its upregulation in metabolic-associated steatohepatitis (MASH) remain elusive., [Methods]: Multiplex transcriptomics and targeted metabolomics analysis of liver biopsies in dietary mouse models representing the whole spectra of MASLD were carried out to characterize the relevance of hepatic GLS during disease pathological progression. In addition, the acute effect of liver-specific GLS inhibition in hepatic ammonia content was evaluated in cultured hepatocytes and in in vivo mouse models of diet-induced MASLD. Finally, the regulatory mechanisms of hepatic GLS overexpression related to the lipopolysaccharide (LPS)/Toll-like receptor 4 (TLR4) axis were explored in the context of MASH., [Results]: In mouse models of diet-induced MASLD, we found that augmented liver GLS expression is closely associated with the build-up of hepatic ammonia as the disease progresses from steatosis to steatohepatitis. Importantly, the acute silencing/pharmacological inhibition of GLS diminishes the ammonia burden in cultured primary mouse hepatocytes undergoing dedifferentiation, in steatotic hepatocytes, and in a mouse model of diet-induced steatohepatitis, irrespective of changes in ureagenesis and gut permeability. Under these conditions, GLS upregulation in the liver correlates positively with the hepatic expression of TLR4 that recognizes LPS. In agreement, the pharmacological inhibition of TLR4 reduces GLS and hepatic ammonia content in LPS-stimulated mouse hepatocytes and hyperammonemia animal models of endotoxemia., [Conclusions]: Overall, our results suggest that the LPS/TLR4 axis regulates hepatic GLS expression promoting liver ammonia build-up as steatotic liver disease progresses to steatohepatitis., TC Delgado is funded by “Ayuda RYC2020-029316-I financiada por MCIN/AEI/10.13039/501100011033 y por El FSE invierte en tu future”. This work was supported by the Gilead Sciences Research Scholars Program in Global Liver (to TCD), Nanostring® grant (to TCD); grant from Ministerio de Ciencia, Innovación y Universidades (MICINN: PID2022-139395OB-100 integrado en el Plan Estatal de Investigación Científica y Técnica e Innovación, con Fondos FEDER); grants from Ministerio de Ciencia, Innovación y Universidades MICINN: PID2020-117116RB-I00 CEX2021-001136-S integrado en el Plan Estatal de Investigación Científica y Técnica e Innovación, cofinanciado con Fondos FEDER for (MLM-C); Project funded by CIBEREHD; La Caixa Scientific Foundation (HR17-00601) (for MLM-C); ERA-Net E-Rare EJP RD Joint Translational Call for Rare Diseases FIGHT-CNNM2 (EJPRD19-040), and from Instituto Carlos III, Spain (for MLM-C, JH); the Basque Department of Education (IT1739-22) (for JH). JH and TCD are members of the European Reference Network for Rare Hereditary Metabolic Disorders (MetabERN) Project ID No. 739543., With funding from the Spanish government through the "Severo Ochoa Centre of Excellence" accreditation (CEX2021-001136-S)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Metallothionein-3 is a multifunctional driver that modulates the development of sorafenib-resistant phenotype in hepatocellular carcinoma cells

  • Merlos Rodrigo, Miguel Angel
  • Michalkova, Hana
  • Jiménez Jiménez, Ana María
  • Petrlak, Frantisek
  • Do, Tomas
  • Sivak, Ladislav
  • Haddad, Yazan
  • Kubickova, Petra
  • Ríos, Vivian de los
  • Casal, J. Ignacio
  • Serrano-Macia M.
  • Delgado, Teresa C.
  • Boix, Loreto
  • Bruix, Jordi
  • Martínez-Chantar, María L.
  • Adam, Vojtech
  • Heger, Z.
18 p.-7 fig., Background & aims: Metallothionein-3 (hMT3) is a structurally unique member of the metallothioneins family of low-mass cysteine-rich proteins. hMT3 has poorly characterized functions, and its importance for hepatocellular carcinoma (HCC) cells has not yet been elucidated. Therefore, we investigated the molecular mechanisms driven by hMT3 with a special emphasis on susceptibility to sorafenib., Methods: Intrinsically sorafenib-resistant (BCLC-3) and sensitive (Huh7) cells with or without up-regulated hMT3 were examined using cDNA microarray and methods aimed at mitochondrial flux, oxidative status, cell death, and cell cycle. In addition, in ovo/ex ovo chick chorioallantoic membrane (CAM) assays were conducted to determine a role of hMT3 in resistance to sorafenib and associated cancer hallmarks, such as angiogenesis and metastastic spread. Molecular aspects of hMT3-mediated induction of sorafenib-resistant phenotype were delineated using mass-spectrometry-based proteomics., Results: The phenotype of sensitive HCC cells can be remodeled into sorafenib-resistant one via up-regulation of hMT3. hMT3 has a profound effect on mitochondrial respiration, glycolysis, and redox homeostasis. Proteomic analyses revealed a number of hMT3-affected biological pathways, including exocytosis, glycolysis, apoptosis, angiogenesis, and cellular stress, which drive resistance to sorafenib., Conclusions: hMT3 acts as a multifunctional driver capable of inducing sorafenib-resistant phenotype of HCC cells. Our data suggest that hMT3 and related pathways could serve as possible druggable targets to improve therapeutic outcomes in patients with sorafenib-resistant HCC., The authors acknowledge funding from the European Research Council (ERC) under the European Union´s Horizon 2020 Research and Innovation Programme (grant agreement No. 759585), the Czech Science Foundation (project no. 19–13766 J), Mendel University in Brno (project no. AF-IGA2020-IP020), and EMBO - European Molecular Biology Organization. Ministerio de Ciencia e Innovación, Programa Retos-Colaboración RTC2019-007125-1; Instituto de Salud Carlos III, Proyectos de Investigación en Salud DTS20/00138; Ministerio de Ciencia, Innovación y Universidades MICINN: PID2020-117116RB-I00; La Caixa Foundation Program., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Metabolic dysfunction-associated steatotic liver disease alters brain function and behavior: Insights from liver-targeted siRNA therapy

  • Cardoso Delgado, Teresa de Jesús
  • Martín-Cuevas, Celia
  • Sánchez-Hidalgo, Ana C.
  • Gil-Gómez, Antonio
  • Rejano-Gordillo, Claudia María
  • Landa, Jon
  • Gallego-Durán, Rocío
  • Goikoetxea-Usandizaga, Naroa
  • González-Recio, Irene
  • Gil-Pitarch, Clàudia
  • Zapata-Pavas, L. Estefanía
  • Barrenechea-Barrenechea, Jon Ander
  • Conter, Carolina
  • Martínez-Cruz, Luis Alfonso
  • Ramos Herrero, Víctor
  • Nogueiras, Rubén
  • Azkargorta, Mikel
  • Elortza, Félix
  • Moncho-Amor, Verónica
  • Crespo, Javier
  • Matheu, Ander
  • Romero-Gómez, Manuel
  • Crespo-Facorro, Benedicto
  • Martínez-Chantar, María Luz
[Data and materials availability:] The mass spectrometry proteomics data have been deposited in the ProteomeXchange Consortium via the PRIDE [1] partner repository with the dataset identifier PXD063321 (www.ebi.ac.uk/pride/archive/projects/PXD063321). All data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials., Metabolic dysfunction–associated steatotic liver disease (MASLD), a liver-centric condition, is associated with cognitive impairment and sensorimotor alterations. However, it remains unclear whether MASLD is sufficient to drive central nervous system deficits. Here, using diet-induced mouse models, we showed that MASLD was associated with alterations in social memory, sensorimotor processing, and hippocampal function, including decreased parvalbumin-positive interneurons, reduced dendritic spine density, and diminished dentate gyrus neurogenesis and neuronal differentiation. Then, we selectively modulated liver metabolism through N-acetylgalactosamine small interfering RNA (siRNA) therapy against Cyclin M4 (CNNM4), a magnesium transporter dysregulated in MASLD. Liver-specific intervention with siRNA-Cnnm4 reversed impaired social memory and sensorimotor processing in association with recovery of hippocampal synaptogenesis and mitochondrial function pathways, alongside activation of neurogenesis-associated transcriptional programs. Our findings demonstrate that liver pathology is sufficient to drive neurobehavioral and hippocampal dysfunction in MASLD. Hepatic-specific intervention restores brain function, strongly supporting the existence of a causal and therapeutically targetable liver-brain axis for MASLD-associated neurological complications., This work was supported by grants from Ministerio de Ciencia, Innovación y Universidades MICINN: CEX2021-001136-S (to M.L.M.-C.) and MICINN: PID2022-139395OB-100 (to M.L.M.-C.); integrado en el Plan Estatal de Investigación Científica y Técnica e Innovación, cofinanciado con Fondos FEDER; and Project funded by CIBEREHD; 2018 BBVA Foundation Grants for Scientific Research Teams- UMBRELLA (to M.L.M.-C., M.R.G., and B.C.-F.). T.C.D. is funded by “Ayuda RYC2020-029316-I financiada por MCIN/AEI/10.13039/501100011033 y por El FSE invierte en tu futuro.” This work was supported by grants from Ministerio de Ciencia, Innovación y Universidades MICINN: PID2020-117116OB-I00 (to T.C.D.). C.M.-C. was supported by CIBERSAM (G26) and the Instituto de Salud Carlos III (AC23_2/00034). A.C.S.H. received funding from CIBERSAM (G26) and the Consejería de Salud y Familias (RH-0063). V.D.R.H. was supported by the Agencia Estatal de Investigación (PID2019-109405R and PI-0014-2022). L.E.Z.-P. was supported by a PhD fellowship from the Provincial Section of Bizkaia from the Scientific Foundation of the Spanish Association Against Cancer PRDVZ233980ZAPA. C.M.R.G. was supported by Ayuda Juan de la Cierva JDC2023-052761-I from the MCIN/AEI/10.13039/501100011033–Unión Europea NextGenerationEU/PRTR. V.M.-A. was supported by the Miguel Servet contract (CP23/00111) from the ISCIII. This project has also received funding from the European Horizon’s research and innovation program HORIZON-HLTH-2022-STAYHLTH-02 (agreement no. 101095679), Spanish Instituto de Salud Carlos III-FEDER Grant (FIS-PI22/01853) and European Union-NextGenerationEU (PMP21/00112) (to J.C.)., With funding form the Spanish government through the "Severa Ochoa Centre of Excellence" accreditation (CEX2021-001136-S)., Peer reviewed
Docta Complutense
Publicación Artículo científico (JournalArticle)

The outcome of boosting mitochondrial activity in alcohol-associated liver disease is organ-dependent

  • Goikoetxea Usandizaga, Naroa
  • Bravo, Miren
  • Egia Mendikute, Leire
  • Abecia, Leticia
  • Serrano Maciá, Marina
  • Urdinguio, Rocío G.
  • Clos García, Marc
  • Rodríguez Agudo, Rubén
  • Araujo Legido, Raquel
  • López Bermudo, Lucía
  • Delgado, Teresa C.
  • Lachiondo Ortega, Sofía
  • González Recio, Irene
  • Gil Pitarch, Clàudia
  • Peña Cearra, Ainize
  • Simón, Jorge
  • Benede Ubieto, Raquel
  • Ariño, Silvia
  • Herranz, Jose M.
  • Azkargorta, Mikel
  • Salazar Bermeo, Julio
  • Martí, Nuria
  • Varela Rey, Marta
  • Falcón Pérez, Juan M.
  • Lorenzo, Óscar
  • Nogueiras, Rubén
  • Elortza, Félix
  • Nevzorova, Yulia
  • Cubero Palero, Francisco Javier
  • Saura, Domingo
  • Martínez Cruz, Luis Alfonso
  • Sabio, Guadalupe
  • Palazón, Asís
  • Sancho Bru, Pau
  • Elguezabal, Natalia
  • Fraga, Mario F.
  • Ávila, Matías A.
  • Bataller, Ramón
  • Marín, José J.G.
  • Martín, Franz
  • Martínez Chantar, María Luz
Background and Aims: Alcohol-associated liver disease (ALD) accounts for 70% of liver-related deaths in Europe, with no effective approved therapies. Although mitochondrial dysfunction is one of the earliest manifestations of alcohol-induced injury, restoring mitochondrial activity remains a problematic strategy due to oxidative stress. Here, we identify methylation-controlled J protein (MCJ) as a mediator for ALD progression and hypothesize that targeting MCJ may help in recovering mitochondrial fitness without collateral oxidative damage. Approach and Results: C57BL/6 mice [wild-type (Wt)] Mcj knockout and Mcj liver-specific silencing (MCJ-LSS) underwent the NIAAA dietary protocol (Lieber-DeCarli diet containing 5% (vol/vol) ethanol for 10 days, plus a single binge ethanol feeding at day 11). To evaluate the impact of a restored mitochondrial activity in ALD, the liver, gut, and pancreas were characterized, focusing on lipid metabolism, glucose homeostasis, intestinal permeability, and microbiota composition. MCJ, a protein acting as an endogenous negative regulator of mitochondrial respiration, is downregulated in the early stages of ALD and increases with the severity of the disease. Whole-body deficiency of MCJ is detrimental during ALD because it exacerbates the systemic effects of alcohol abuse through altered intestinal permeability, increased endotoxemia, and dysregulation of pancreatic function, which overall worsens liver injury. On the other hand, liver-specific Mcj silencing prevents main ALD hallmarks, that is, mitochondrial dysfunction, steatosis, inflammation, and oxidative stress, as it restores the NAD+/NADH ratio and SIRT1 function, hence preventing de novo lipogenesis and improving lipid oxidation. Conclusions: Improving mitochondrial respiration by liver-specific Mcj silencing might become a novel therapeutic approach for treating ALD.